Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

AcelRx Pain Treatment Meets Late-Stage Study Goals

By Pharmaceutical Processing | May 21, 2013

Shares of AcelRx Pharmaceuticals Inc. hit an all-time high price Tuesday, after the specialty drugmaker said its NanoTab pain treatment system met its main goal in late-stage research, and the company is preparing to submit it to regulators for approval.

The Redwood City, Calif., company said patients using the system experienced a significantly greater reduction in pain following major orthopedic surgery compared with those taking a placebo or fake drug.

The NanoTab device is designed to treat severe pain following surgery by delivering a preset dose of the drug sufentanil beneath the patient’s tongue. The patient operates the device by pressing a button. AcelRx says the system is less invasive than intravenous dosing and less prone to dosing errors.

In late 2012 and early 2013, the company also said the NanoTab system met its main goals in two late-stage clinical trials involving patients who’d had major open abdominal surgery.

AcelRx, which focuses on developing pain treatments, said Tuesday that the company remains on track to submit an application for approval of the NanoTab system to regulators in the third quarter.

Company shares reached an all-time high of $7.42 Tuesday morning before retreating to $6.78. That still represented a gain of about 5 percent, or 32 cents, compared with Monday’s closing price.

AcelRx shares began trading in early 2011 after an initial public offering of the stock was priced at $5 per share. The stock closed 2012 below that price at $4.26, but the price has since climbed more than 50 percent.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE